Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Sales and Divestitures: 2020-2024

Historic Gains from Sales and Divestitures for Adma Biologics (ADMA) over the last 5 years, with Dec 2024 value amounting to $1.9 million.

  • Adma Biologics' Gains from Sales and Divestitures rose 8.15% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 8.15%. This contributed to the annual value of $1.9 million for FY2024, which is 57.28% up from last year.
  • Adma Biologics' Gains from Sales and Divestitures amounted to $1.9 million in FY2024, which was up 57.28% from $1.2 million recorded in FY2023.
  • Over the past 5 years, Adma Biologics' Gains from Sales and Divestitures peaked at $2.7 million during FY2022, and registered a low of $15,000 during FY2020.
  • Over the past 3 years, Adma Biologics' median Gains from Sales and Divestitures value was $1.9 million (recorded in 2024), while the average stood at $1.9 million.
  • Per our database at Business Quant, Adma Biologics' Gains from Sales and Divestitures skyrocketed by 2,840.61% in 2022 and then plummeted by 56.02% in 2023.
  • Adma Biologics' Gains from Sales and Divestitures (Yearly) stood at $15,000 in 2020, then skyrocketed by 518.33% to $92,750 in 2021, then surged by 2,840.61% to $2.7 million in 2022, then slumped by 56.02% to $1.2 million in 2023, then skyrocketed by 57.28% to $1.9 million in 2024.